세계의 고령자용 의약품 시장 - 규모, 점유율, 동향 분석 보고서 : 치료제별, 병태별, 유통 채널별, 지역별, 부문 예측(2024-2030년)

Geriatric Medicine Market Growth & Trends:

The global geriatric medicine market size is expected to reach USD 260.0 billion by 2030, registering a CAGR of 7.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increase in the global geriatric population is one of the major challenges for the healthcare industry and the governments across the globe, however, it has proven to be a boon for the geriatric medicine market.

The high market growth is anticipated on account of the rising prevalence of various target diseases in the geriatric population, the demographic shift, the upward trend in lifestyle-related risk factors, and the significantly improved access to affordable healthcare as well as medicine across the developing and emerging economies.

The rising prevalence of the Alzheimer's disease in the geriatric population is expected to serve as a high impact rendering driver for the geriatric medicine market over the forecast period. In 2015, as per the estimates published by the Alzheimer's disease International, nearly 47 million people have dementia and this number is expected to double after every 20 years. Furthermore, as per the estimates published by The Alzheimer's Association, in the U.S., out of the 5.4 million Americans living with the disease, nearly 5.2 million or 96.3% are aged 65 and above.

In order to mitigate the concerns arising due to the unfavorable shift in the demographic variables such as age, lifestyle patterns, economic development, coupled with the upward shift in the disease trends associated with the geriatric population, the developed regions have consistently improved their healthcare practices by allocating high amount of resources towards the healthcare and social development sectors.

For instance, the U.S., Germany, the UK, and Japan allocate 17.1%, 11.30%,9.10%,10.20%, of their GDP respectively towards healthcare expenditure and majority of these resources are channelized towards developing new drugs, new software, and building technology platforms for hospitals and home health services.

Geriatric Medicine Market Report Highlights:

• In the therapeutic category, antihypertensive therapeutics accounted for a share of 20.2% in 2023. These are used for treating high and low blood pressure. There are a variety of antihypertensive drugs available in the market.
• In 2023, North America dominated the geriatric medicine market with a revenue share of over 38.7% owing to the presence of well-developed social and healthcare sectors, the availability of the latest medicine, and insurance coverage coupled with the presence of a large number of people aged above 60 years.
• Asia Pacific region is anticipated to exhibit the maximum growth rate at a CAGR of over 9.1% from the year 2024 to 2030. In comparison with the developed regions, the economic burden of the target diseases, the access to healthcare, health insurance and the percentage of public and private healthcare expenditures vary significantly in the Asia Pacific countries.
• The countries such as China and India are expected to witness a significant rise in the elderly population base and this factor in turn is expected to create an upward trend in the geriatric medicine market over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Global Geriatric Medicine Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Global Geriatric Medicine Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Global Geriatric Medicine Market: Therapeutics Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Geriatric Medicine Market: Therapeutics Movement Analysis, 2023 & 2030 (USD Million)
• 4.3. Analgesics
  • 4.3.1. Analgesics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Antihypertensive
  • 4.4.1. Antihypertensive Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Statins
  • 4.5.1. Statins Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Antidiabetic
  • 4.6.1. Antidiabetic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Proton Pump Inhibitors (PPI)
  • 4.7.1. Proton Pump Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Anticoagulant
  • 4.8.1. Anticoagulant Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Antipsychotic
  • 4.9.1. Antipsychotic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.10. Others
  • 4.10.1. Antidiabetic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Global Geriatric Medicine Market: Condition Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Geriatric Medicine Market: Condition Movement Analysis, 2023 & 2030 (USD Million)
• 5.3. Cardiovascular Disease
  • 5.3.1. Cardiovascular Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Arthritis and Bone Health
  • 5.4.1. Arthritis and Bone Health Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Neurological Disorders
  • 5.5.1. Neurological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Cancer
  • 5.6.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Diabetes and Metabolic Disorders
  • 5.7.1. Diabetes & Metabolic Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Respiratory Diseases
  • 5.8.1. Respiratory Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Global Geriatric Medicine Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Geriatric Medicine Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
• 6.3. Hospital Pharmacy
  • 6.3.1. Hospital pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Retail Pharmacy
  • 6.4.1. Retail pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Online
  • 6.5.1. Online Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Global Geriatric Medicine Market: Regional Estimates & Trend Analysis

• 7.1. Global Geriatric Medicine Market Share, By Region, 2023 & 2030, USD Million
• 7.2. North America
  • 7.2.1. North America Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Canada Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. UK Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Germany Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. France Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Italy Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Spain Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Norway Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. China
    • 7.4.2.1. China Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Japan
    • 7.4.3.1. Japan Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. India Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.6. Australia
    • 7.4.6.1. Australia Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.7. Thailand
    • 7.4.7.1. Thailand Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Middle East and Africa
  • 7.6.1. Middle East and Africa Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Saudi Arabia
    • 7.6.2.1. Saudi Arabia Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. UAE
    • 7.6.3.1. UAE Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. South Africa
    • 7.6.4.1. South Africa Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Global Geriatric Medicine Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Heat Map Analysis
• 8.4. Company Profiles
  • 8.4.1. F. Hoffmann-La Roche Ltd.
    • 8.4.1.1. Participant's Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Recent Developments/ Strategic Initiatives
  • 8.4.2. Novartis AG
    • 8.4.2.1. Participant's Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Recent Developments/ Strategic Initiatives
  • 8.4.3. AbbVie Inc.
    • 8.4.3.1. Participant's Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Recent Developments/ Strategic Initiatives
  • 8.4.4. Johnson & Johnson Services, Inc.
    • 8.4.4.1. Participant's Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Recent Developments/ Strategic Initiatives
  • 8.4.5. Merck and Co., Inc.
    • 8.4.5.1. Participant's Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Recent Developments/ Strategic Initiatives
  • 8.4.6. Pfizer, Inc.
    • 8.4.6.1. Participant's Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Recent Developments/ Strategic Initiatives
  • 8.4.7. Bristol-Myers Squibb Company
    • 8.4.7.1. Participant's Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Recent Developments/ Strategic Initiatives
  • 8.4.8. Sanofi
    • 8.4.8.1. Participant's Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Recent Developments/ Strategic Initiatives
  • 8.4.9. GSK plc
    • 8.4.9.1. Participant's Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Recent Developments/ Strategic Initiatives
  • 8.4.10. Takeda Pharmaceutical Company Limited
    • 8.4.10.1. Participant's Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Recent Developments/ Strategic Initiatives